Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to $4.0 million.

  • Abvc Biopharma's Accounts Payables rose 1117.21% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 1117.21%. This contributed to the annual value of $3.5 million for FY2024, which is 109.71% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Accounts Payables is $4.0 million, which was up 1117.21% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Accounts Payables registered a high of $4.3 million during Q2 2025, and its lowest value of $2085.0 during Q2 2022.
  • Over the past 5 years, Abvc Biopharma's median Accounts Payables value was $3.5 million (recorded in 2023), while the average stood at $2.5 million.
  • In the last 5 years, Abvc Biopharma's Accounts Payables crashed by 5868.83% in 2022 and then surged by 1816.81% in 2025.
  • Abvc Biopharma's Accounts Payables (Quarter) stood at $16497.0 in 2021, then plummeted by 87.36% to $2085.0 in 2022, then surged by 170084.75% to $3.5 million in 2023, then decreased by 1.1% to $3.5 million in 2024, then increased by 13.73% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.3 million for Q2 2025, and $3.8 million during Q1 2025.